Preventing Clinically Important Deterioration of COPD with Addition of Umeclidinium to Inhaled Corticosteroid/Long-Acting β2-Agonist Therapy: An Integrated Post Hoc Analysis
Crossref DOI link: https://doi.org/10.1007/s12325-018-0771-4
Published Online: 2018-09-06
Published Print: 2018-10
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Naya, Ian P.
Tombs, Lee
Lipson, David A.
Compton, Chris
Funding for this research was provided by:
GSK (study number: 202067)
Article History
Received: 2 July 2018
First Online: 6 September 2018